Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00127803
Other study ID # H-030-008
Secondary ID
Status Completed
Phase Phase 1
First received August 5, 2005
Last updated September 7, 2012
Start date July 2005
Est. completion date March 2006

Study information

Verified date September 2012
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerability of a modified C. difficile vaccine at 3 dose levels compared with a placebo control administered via intramuscular injection in healthy adults aged 18-55 years of age.


Description:

Clostridium difficile is the leading infectious cause of nosocomial diarrhea in developed countries. Hospital outbreaks of Clostridium difficile-associated diarrhea (CDAD) are associated with substantial patient morbidity and mortality. Conventional therapy with antibiotics often results in secondary infection with resistant organisms or clinical relapse after discontinuation of the antimicrobial course. New strategies are needed to limit the impact of this opportunistic pathogen. Considerable evidence exists that immunity against C. difficile toxins may be effective in controlling CDAD. 48 subjects will be enrolled to receive one of three dose levels of modified C difficile vaccine or placebo administered on a 3-dose schedule. The study consists of a 30-day screening period, a 70-day treatment period, one follow-up phone interview 2 months after the last vaccination, and one follow-up clinic visit 6 months after the last vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 2006
Est. primary completion date January 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Adult males or females, 18-55 years (inclusive)

- In good general health

- Clinical lab tests within normal range

- Non-pregnant female subjects

- Able and willing to participate for duration of study and must not participate in any other experimental study for at least 60 days after receiving the last dose of study vaccine

Exclusion Criteria:

- Evidence of C. difficile infection

- Evidence of any previous antibiotic-associated diarrhea

- Active or inactive inflammatory bowel disease, irritable colon syndrome, chronic abdominal pain or other chronic diarrhea

- History of malignancy within 5 years

- History of anaphylaxis, asthma or severe vaccine or severe allergic drug reaction

- Known or suspected history of immunodeficiency;

- Active or inactive immune-mediated or inflammatory disease;

- Pregnant or lactating female subjects;

- History of drug or alcohol abuse disorders;

- Serology positive for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)

- Receipt of antibiotic therapy or an investigational drug within prior 30 days

- Blood or organ donation within prior 30 days

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Placebo (vaccine diluent)
0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
Clostridium difficile vaccine
0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
Clostridium difficile vaccine
0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
Clostridium difficile vaccine
0.5 mL, intramuscular on Days 0, 28, and 56, respectively.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Reporting Solicited Injection Site Erythema and Tenderness Post-vaccination With Either One of Three Formulations of Clostridium Difficile Vaccines or a Placebo Vaccine. Day 0 and up to 7 days post each vaccination No
Primary Number of Participants Reporting Treatment-Emergent Adverse Events Post-vaccination With Either One of Three Formulations of the Clostridium Difficile Vaccine or a Placebo Vaccine. Day 0 to up to 70 days post-first vaccination No
Secondary Number of Participants With Seroconversion for Toxin A and Toxin B Post-vaccination With Either One of Three Formulations of the Clostridium Difficile Vaccine or a Placebo Vaccine. Seroconversion was defined as a =4-fold increase in antibody levels from Baseline. For values below the limit of quantification (LLQ) for the assay, the LLQ was used.
Serum anti-toxin IgG levels were determined by enzyme linked immunosorbent assay (ELISA).
Days 28, 56, 70, and 236 Post First Vaccination No
See also
  Status Clinical Trial Phase
Recruiting NCT04179201 - Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
Completed NCT02563106 - A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI Phase 2
Completed NCT00214461 - Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers Phase 1
Completed NCT00314951 - Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT00328263 - Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients Phase 3
Completed NCT00350298 - Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Phase 2
Withdrawn NCT05077085 - Bezlotoxumab Versus FMT for Multiple Recurrent CDI Phase 4
Recruiting NCT02681068 - MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation N/A
Completed NCT00446355 - Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes N/A
Terminated NCT00384527 - Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease Phase 3
Completed NCT00269399 - A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT04026009 - Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years Phase 1
Recruiting NCT06277999 - C.Difficile Observational Study
Completed NCT00468728 - PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3

External Links